E-4177
| Code | Size | Price |
|---|
| TAR-T27229-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27229-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27229-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
E-4177 is an angiotensin type 1 receptor antagonist. In rat adrenal cortex and liver, E4177 competitively inhibited the specific binding of 125I-[Sar1,Ile8]Ang II, with IC50 being (5.2 +/- 1.0) x 10(-8) M for the adrenal cortex and (1.2 +/- 0.3) x 10(-7) M for the liver.
CAS:
135070-05-2
Formula:
C24H21N3O2
Molecular Weight:
383.451
Purity:
0.98
SMILES:
Cc1ccnc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(nc12)C1CC1
References
1. Kuma S, Oki E, Onohara T, Komori K, Maehara Y. Angiotensin II-induced growth of vascular smooth muscle cells is associated with modulation of cell surface area and platelet-derived growth factor receptor expression. Clin Exp Pharmacol Physiol. 2007 Mar;34(3):153-60. PubMed PMID: 17250632.
2. Tanaka M, Umemoto S, Kawahara S, Kubo M, Itoh S, Umeji K, Matsuzaki M. Angiotensin II type 1 receptor antagonist and angiotensin-converting enzyme inhibitor altered the activation of Cu/Zn-containing superoxide dismutase in the heart of stroke-prone spontaneously hypertensive rats. Hypertens Res. 2005 Jan;28(1):67-77. PubMed PMID: 15969257.
3. Matsuda H, Hayashi K, Arakawa K, Naitoh M, Kubota E, Honda M, Matsumoto A, Suzuki H, Yamamoto T, Kajiya F, Saruta T. Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin. J Am Soc Nephrol. 1999 Nov;10(11):2272-82. PubMed PMID: 10541285.
4. Matsumoto K, Morishita R, Moriguchi A, Tomita N, Yo Y, Nishii T, Nakamura T, Higaki J, Ogihara T. Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats. Hypertension. 1999 Aug;34(2):279-84. PubMed PMID: 10454454.